Radioactive therapeutic liposomes

Details Radioactive therapeutic liposomes Radioactive therapeutic liposomes

2001-02-21

2003-07-15

Hartley, Michael G. (Department: 1616)

Drug, bio-affecting and body treating compositions

Radionuclide or intended radionuclide containing; adjuvant...

Molecular bilayer structure

C424S450000

Reexamination Certificate

active

06592843

ABSTRACT:

CROSS REFERENCE TO RELATED APPLICATIONS
This application claims benefit of Norwegian Patent Application No. 2000 0855, filed Feb. 21, 2000.
The present invention relates to a conjugator system comprising liposomes with ionophores and with chelator located inside of the liposomes, wherein the liposomes are stably labeled with heavy radionuclides emitting a particles. The present invention further relates to a method to prepare the conjugator system and use of the system, as well as a kit for preparing the conjugator system.
Biomedical applications of radionuclides in anticancer therapy have so far focused on the use of cationic or anionic species, e.g., [
131
I]iodide against thyroid cancer and
89
Sr for palliation of pain from skeletal cancer metastases, and the use of mostly beta-emitting radionuclides attached to monoclonal antibodies (DeVita et al., 1996).
The use of targeted radionuclide therapy against cancer rest upon the ability to find ways to attach radionuclides to tumor specific carrier compounds (Gaze, 1996). Today, some of the radionuclides with useful radiation characteristics cannot be used in tumor targeting because of the problem of providing a chemically stable link between the radionuclide and the carrier compound. Now carrier systems may, however, broaden both the use of radioisotopes, as well as the arsenal of radionuclides considered useful for therapy (Gaze, 1996).
Liposomes, with or without receptor affinic groups attached to the surface, have been evaluated for drug delivery, and is currently used clinically for the delivery of chemotherapeutics in some cancer forms. Recently, developments in liposome research have led to new versions with a pharmacokinetics which could make these compounds useful as carriers for radionuclide for internal radiotherapy against cancer (Gabizon, 1995). These recent developments in the formulation and manufacturing of liposomes have resulted in small vesicles of less than 100 nm with prolonged circulation time, as the size of the liposomes can be better confined to small diameters by using extrusion through membranes. Furthermore, the introduction of poly ethylene glycol (PEG) grafted liposomes has reduced the interference from plasma proteins, and thus reduced the recognition and clearance affected by the macrophages of the reticuloendothelial system (Maruyama, et al., 1997). Increased levels of tumor uptake due to sustained blood concentration have thereby been achieved. Even further tumor uptake has boon achieved by conjugating molecules with receptor affinity, e.g., monoclonal antibodies or folate, to the surface of the liposomes. In addition, several studies have indicated the advantage of applying PEG as a linker between the lipsome and the targeting ligand, since this also can improve the receptor accessibility (e.g. Maruyama et al, 1997; Gabison et al, 1999; Lee et al, 1994).
Liposomes have previously been studied as carriers for radioisotopes (Goins et al, 1998; Turner et al, 1988). Pikul, et al (1987) reported a study based on
212
Pb-dextran incorporated passively (i.e., the
212
Pb-dextran was added during the generation of the liposome, and a fraction of the
212
Pb-dextran was incorporated together with the aqueous phase representing the interior of the liposome). The authors did not suggest that these liposomes were suitable for cancer therapy, but was using it primarily for studying intracellular cell killing in vitro with radioisotope. No data of the fate of
212
Bi generated from the
212
Pb decay was presented, and the size of the liposomes were in the order of 350-500 nm which is very large compared to the size (approx.100 nm) currently considered optimal for in vivo tumor therapy (Forssen, 1997). Also, the liposomes did not contain PEG in the membrane.
Ogihar-Umeda et al. (1996) used liposomes as carrier for the gamma emitting radionuclides
67
Ga,
111
In and
99m
Tc, and suggested the use of radiolabeled liposomes for imaging.
In a theoretical study, Kostarelos et al. (1999) suggested the use of liposomes labeled with the potentially therapeutically radionucides
131
I,
67
Cu,
138
Re and
211
At, but chemical procedures for the preparation of the radiolabeled liposomes were not suggested.
EP386 146 B1 describes a composition and method of use for liposome encapsulated compounds for neutron capture tumor therapy. However, these liposomes were loaded with stabel elements (e.g. boron), that become radioactive only after activation, and the liposomes contain neither ionophores nor chelator.
Utkhede et al., (1994) describes liposomes loaded with
90
Y and the chelator DTPA, which is a different chelator compared to the chelators described in the present invention. Furthermore, retention of mother/daughternuclide(s) is not described and in addition,
90
Y is not a heavy element as the elements described in the present application.
Achieving sufficiently stable radiolabeling of carriers with heavy alpha-emitting radionuclides usually requires specific chemical procedures tailored to suit the chemistry of each element, and such methods are not known. Procedures used to radiolabel e.g. Ga, In, Te, Cu or Re cannot be expected to be compatible with heavy radionuclide (atomic weight over 150) cationic alpha emitters like e.g.
212/213
Bi,
212
Pb,
223/224
Ra,
227Th
or
225
Ac.
It is therefore an object of the present invention to provide a radionuclide-liposome conjugator system, with or without receptor affinic groups, that (1) encapsulates chelator and heavy radionuclide(s) that emit alpha particle radiation, (2) can retain daughter nuclide(s) when the mother nuclide(s) is incorporated in the liposome and (3) can be prepared by an active incorporation procedure useful for a panel of radionuclides, as well as use of the system and a kit for preparing the system These objects have been obtained by the present invention, characterized by the enclosed claims.
The present invention relates to a conjugator system comprising liposomes with ionophores, i.e., a metal extracting agent for liposomes, and with chelator and heavy radionuclide(s) (atomic weight over 150) located inside the liposome. The liposomes are prepared using active incorporation of the radionuclide, i.e., via ionophores, and prepared according to procedures yielding liposomes of size of typically 100 nm. The resulting product shows good chemical stability over several days, and may also retain daughter nuclide(s) inside the liposome, e.g. from the transformation of
212
Pb to
212
Bi. The liposomes can be prepared with or without modifying groups like polyalkylene oxides, e.g., PEG, attached to the membrane. Herein we also describe a method to link such radiolabeled liposomes to tumor seeking proteins, such as e.g. folate conjugated monoclonal antibodies.


REFERENCES:
patent: 4310506 (1982-01-01), Baldeschwieler et al.
patent: 5608060 (1997-03-01), Axworthy et al.
patent: 0 386 146 (1990-09-01), None
Deal et al., “Improved in vivo Stability of Actinium-225 Macrocyclic Complexes,”J. Med. Chem.42:2988-2992 (1999).
Bartlett, “Phosphours Assay in Column Chromatography,”J. Biol. Chem., 234:466-468 (1958).
Cabell, “The Purification, Determination, And Neutron Capture Cross Section Of Actinium-227,”Can. J. Chem., 37:1094-1103 (1959).
Dietz et al., “Improved Chemistry for the Production of Yttrium-90 for Medical Applications,”Appl. Radiat. Isot., 43:1093-1101 (1992).
Forssen, “The Design and Development of DaunoXome® for Solid Tumor Targeting In Vivo,”Adv. Drug Delivery Rev., 24:133-150 (1997).
Gabizon et al., “Targeting Folate Receptor with Folate Linked to Extremities of Poly(ethylene glycol)-Grafted Liposomes: In Vitro Studies,”Bioconjugate Chem., 10:289-298 (1999).
Gabizon, “Liposome Circulation Time and Tumor Targeting: Implications for Cancer Chemotherapy,”Adv. Drug Delivery Rev., 16:285-294 (1995).
Gaze, “The Current Status of Targeted Radiotherapy in Clinical Practice,”Phys. Med. Biol., 41:1895-1903 (1996).
Goins et al., “Repeat Injection Studies of Technetium-99M-Labeled PEG-Liposomes in the Same Animal,”J. Liposome Res., 8:265-281

Affiliated with

Also associated with

Rating

Radioactive therapeutic liposomes does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with Radioactive therapeutic liposomes, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Radioactive therapeutic liposomes will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3074999